RT Journal Article
SR Electronic
T1 Radiation Pneumonitis After Volumetric Modulated Arc Therapy for Non-small Cell Lung Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5793
OP 5802
DO 10.21873/anticanres.15396
VO 41
IS 11
A1 MASAYUKI FUJIWARA
A1 HIROSHI DOI
A1 MASATAKA IGETA
A1 HITOMI SUZUKI
A1 KAZUHIRO KITAJIMA
A1 MASAO TANOOKA
A1 TOSHIHISA ISHIDA
A1 TSUKASA WAKAYAMA
A1 TAKASHI YOKOI
A1 KOZO KURIBAYASHI
A1 TAKASHI KIJIMA
A1 MASAKI HASHIMOTO
A1 NOBUYUKI KONDO
A1 SEIJI MATSUMOTO
A1 SEIKI HASEGAWA
A1 NORIHIKO KAMIKONYA
A1 KOICHIRO YAMAKADO
YR 2021
UL http://ar.iiarjournals.org/content/41/11/5793.abstract
AB Background/Aim: To evaluate the incidence and grade of radiation pneumonitis after volumetric modulated arc therapy (VMAT) performed for the treatment of non-small cell cancer (NSCLC). Patients and Methods: Fifty consecutive non-surgical candidates with NSCLC underwent VMAT. Thirty-five patients had stage-III tumors and 15 had recurrent tumors. The prescribed radiation dose for the gross tumor and the elective nodal area was 69 Gy in 30 fractions and 51 Gy in 30 fractions, respectively. Results: Radiation pneumonitis developed in 38 patients (76%, 38/50), and grade ≥2 radiation pneumonitis developed in 11 patients (22%, 11/50). The percentage of lung volume that received a dose in excess of 5 Gy (V5), V10, V20, V30, and the mean lung dose (MLD) in the bilateral and ipsilateral lung were significantly associated with the development of grade ≥2 radiation pneumonitis. Conclusion: The incidence and degree of radiation pneumonitis are acceptable following treatment of NSCLC with VMAT.